Literature DB >> 6097611

A radioimmunologic technique to screen for antibodies to alpha-2 interferon.

W P Protzman, S L Jacobs, M Minnicozzi, E M Oden, D K Kelsey.   

Abstract

A radioimmunologic technique has been developed to screen sera of persons receiving human alpha-2 interferon for the presence of specific antibodies to alpha-2 interferon. The method is sensitive and easy to perform. It tests the ability of the sera to neutralize alpha-2 interferon and prevent the interferon from being detected by an immunoradiometric assay. The results obtained using this technique are in good agreement with an anti-viral, cytopathic effect assay. Using the immunological technique, the sera from more than 1000 individuals who had received different doses of alpha-2 interferon by one or more of various routes of administration were tested. Twenty-five sera representing 14 individuals gave a positive or possibly positive reaction in the assay. Three of the 14 individuals were positive prior to receipt of alpha-2 interferon. Another 3 had reverted to negative when tested a few months later. Of the remaining 8, only 4 developed titers greater than 100 neutralizing units/ml. Hence approximately 1% of the alpha-2 interferon recipients may have produced neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097611     DOI: 10.1016/0022-1759(84)90115-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

1.  Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.

Authors:  M Freund; P von Wussow; J Knüver-Hopf; H Mohr; U Pohl; G Exeriede; H Link; H J Wilke; H Poliwoda
Journal:  Blut       Date:  1988-11

2.  Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects.

Authors:  J A Thompson; W W Cox; C G Lindgren; C Collins; K A Neraas; E M Bonnem; A Fefer
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.